TSE:CTX Crescita Therapeutics Q3 2025 Earnings Report C$0.79 0.00 (0.00%) As of 06/4/2026 ProfileEarnings History Crescita Therapeutics EPS ResultsActual EPSC$0.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACrescita Therapeutics Revenue ResultsActual Revenue$5.39 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACrescita Therapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time6:00PM ETConference Call ResourcesPress ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Crescita Therapeutics Earnings HeadlinesCrescita Therapeutics Inc. Announces Closing of ArrangementJune 3, 2026 | financialpost.comFCrescita Therapeutics Inc. Announces Closing of ArrangementJune 3, 2026 | financialpost.comFTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 5 at 1:00 AM | Banyan Hill Publishing (Ad)Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActivJune 1, 2026 | financialpost.comFCrescita Therapeutics Inc. Obtains Final Order Approving Plan of ArrangementMay 20, 2026 | financialpost.comFCrescita Obtains Shareholder Approval To Be Acquired By ClinActiv HoldingsMay 14, 2026 | financialpost.comFSee More Crescita Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crescita Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescita Therapeutics and other key companies, straight to your email. Email Address About Crescita TherapeuticsCrescita Therapeutics (TSE:CTX) Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.View Crescita Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
